Skip to main content
Article thumbnail
Location of Repository

SLC2A9 is a high-capacity urate transporter in humans

By Mark J. Caulfield, Patricia B. Munroe, Deb O'Neill, Kate Witkowska, Fadi J. Charchar, Manuel Doblado, Sarah Evans, Susana Eyheramendy, Abiodun Onipinla, Philip Howard, Sue Shaw-Hawkins, Richard J. Dobson, Chris Wallace, Stephen J. Newhouse, Morris Brown, John M. Connell, Anna Dominiczak, Martin Farrall, G. Mark Lathrop, Nilesh J. Samani, Meena Kumari, Michael Marmot, Eric Brunner, John Chambers, Paul Elliot, Jaspal Kooner, Maris Lann, Elin Org, Gudrun Veldre, Margus Viigimaa, Francesco P. Cappucio, Chen Ji, Roberto Iacone, Pasquale Strazullo, Kelle H. Moley and Chris Cheeseman

Abstract

<b>Background</b><br />\ud Serum uric acid levels in humans are influenced by diet, cellular breakdown, and renal elimination, and correlate with blood pressure, metabolic syndrome, diabetes, gout, and cardiovascular disease. Recent genome-wide association scans have found common genetic variants of SLC2A9 to be associated with increased serum urate level and gout. The SLC2A9gene encodes a facilitative glucose transporter, and it has two splice variants that are highly expressed in the proximal nephron, a key site for urate handling in the kidney. We investigated whether SLC2A9 is a functional urate transporter that contributes to the longstanding association between urate and blood pressure in man.<p></p>\ud <b>Methods and Findings</b><br />\ud We expressed both SLC2A9 splice variants in Xenopus laevis oocytes and found both isoforms mediate rapid urate fluxes at concentration ranges similar to physiological serum levels (200–500 μM). Because SLC2A9 is a known facilitative glucose transporter, we also tested whether glucose or fructose influenced urate transport. We found that urate is transported by SLC2A9 at rates 45- to 60-fold faster than glucose, and demonstrated that SLC2A9-mediated urate transport is facilitated by glucose and, to a lesser extent, fructose. In addition, transport is inhibited by the uricosuric benzbromarone in a dose-dependent manner (Ki = 27 μM). Furthermore, we found urate uptake was at least 2-fold greater in human embryonic kidney (HEK) cells overexpressing SLC2A9 splice variants than nontransfected kidney cells. To confirm that our findings were due to SLC2A9, and not another urate transporter, we showed that urate transport was diminished by SLC2A9-targeted siRNA in a second mammalian cell line. In a cohort of men we showed that genetic variants of SLC2A9 are associated with reduced urinary urate clearance, which fits with common variation at SLC2A9 leading to increased serum urate. We found no evidence of association with hypertension (odds ratio 0.98, 95% confidence interval [CI] 0.9 to 1.05, p &gt; 0.33) by meta-analysis of an SLC2A9 variant in six case–control studies including 11,897 participants. In a separate meta-analysis of four population studies including 11,629 participants we found no association of SLC2A9 with systolic (effect size −0.12 mm Hg, 95% CI −0.68 to 0.43, p = 0.664) or diastolic blood pressure (effect size −0.03 mm Hg, 95% CI −0.39 to 0.31, p = 0.82).<p></p>\ud <b>Conclusions</b><br />\ud This study provides evidence that SLC2A9 splice variants act as high-capacity urate transporters and is one of the first functional characterisations of findings from genome-wide association scans. We did not find an association of the SLC2A9 gene with blood pressure in this study. Our findings suggest potential pathogenic mechanisms that could offer a new drug target for gout.<p></p

Publisher: Public Library of Science
Year: 2008
OAI identifier: oai:eprints.gla.ac.uk:18144
Provided by: Enlighten

Suggested articles

Citations

  1. (2004). [Physiology and biochemistry of uric acid].
  2. (2007). A highly conserved hydrophobic motif in the exofacial vestibule of fructose transporting SLC2A proteins acts as a critical determinant of their substrate selectivity. doi
  3. (2006). Abnormalities of renal sodium handling in the metabolic syndrome. Results of the Olivetti Heart Study. doi
  4. (2005). Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. doi
  5. (1999). Allelic discrimination using fluorogenic probes and the 59 nuclease assay. doi
  6. (2008). Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case-control study. doi
  7. (2007). Circulating leptin levels predict the development of metabolic syndrome in middle-aged men: an 8-year follow-up study. doi
  8. (2006). Contribution of intestine and kidney to glucose fluxes in different nutritional states in rat. doi
  9. (1999). Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting. doi
  10. (1990). Differential localization of two glucose transporter isoforms in rat kidney. doi
  11. (2005). Expression of the GLUT1 and GLUT9 facilitative glucose transporters in embryonic chondroblasts and mature chondrocytes in ovine articular cartilage. doi
  12. (2004). Galectin 9 is the sugar-regulated urate transporter/ channel UAT. doi
  13. (2003). Genome-wide mapping of human loci for essential hypertension. doi
  14. (2008). Genomewide association study identifies novel genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. doi
  15. (2001). Gluconeogenesis from glutamine and lactate in the isolated human renal proximal tubule: longitudinal heterogeneity and lack of response to adrenaline. doi
  16. (1992). Glucose transporters of rat proximal tubule: differential expression and subcellular distribution.
  17. (2004). GLUT9 is differentially expressed and targeted in the preimplantation embryo. doi
  18. (2003). Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. doi
  19. (2005). Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. doi
  20. (2007). Hyperuricemia and incidence of hypertension among men without metabolic syndrome. doi
  21. (1966). Hyperuricemia in primary and renal hypertension. doi
  22. (2004). Identification and characterization of human glucose transporterlike protein-9 (GLUT9): alternative splicing alters trafficking. doi
  23. (2008). KBioScience KBioscience: GenotypingChemistry. Available: http://www.kbioscience.co.uk/chemistry/chemistry_Kasp_intro. html.
  24. (2003). Measuring inconsistency in meta-analyses.
  25. (2002). Molecular identification of a renal urate anion exchanger that regulates blood urate levels. doi
  26. (2006). Mouse glucose transporter 9 splice variants are expressed in adult liver and kidney and are up-regulated in diabetes. doi
  27. (2007). New insights into renal transport of urate. doi
  28. (1981). Pharmacokinetics and biotransformation of benzbromarone in man. doi
  29. (2007). Plasma uric acid and the risk of type 2 diabetes in a Chinese community.
  30. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. doi
  31. (1999). Presence of fructose transporter GLUT5 in the S3 proximal tubules in the rat kidney. doi
  32. (2005). Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. doi
  33. (2001). Renal Na(þ)-glucose cotransporters.
  34. (2005). Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? doi
  35. (2000). Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. doi
  36. (1994). Serum uric acid and hypertension: the Olivetti heart study. doi
  37. (2003). Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. doi
  38. (2008). SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. doi
  39. (2008). SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. doi
  40. (2003). Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli.
  41. (2008). Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: The third national health and nutrition examination survey. doi
  42. (2007). The expression of GLUT8, GLUT9a, and GLUT9b in the mouse testis and sperm. doi
  43. (2007). The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. doi
  44. (1994). The human kidney low affinity Naþ/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. doi
  45. (2000). The Xenopus oocyte expression system for the cDNA cloning and characterization of plasma membrane transport
  46. (2003). Urate transport via human PAH transporter hOAT1 and its gene structure. doi
  47. (1993). Uric acid metabolism and tubular sodium handling. Results from a population-based study. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.